| Not Yet Recruiting | OT-101 in Combination With Pembrolizumab in Subjects With Malignant Pleural Mesothelioma Failing to Respond to NCT05425576 | Oncotelic Inc. | Phase 2 |
| Recruiting | Hemithoracic Arc Radiotherapy Post Pleural Decortication NCT06910449 | Cairo University | N/A |
| Recruiting | Hemithoracic Irradiation With Proton Therapy in Malignant Pleural Mesothelioma NCT05655078 | University College, London | N/A |
| Recruiting | Study of Pembrolizumab Plus Chemotherapy With Lenvatinib for Malignant Pleural Mesothelioma NCT06318286 | Hyogo Medical University | Phase 2 |
| Recruiting | Using E-Nose Technology to Measure Response to Treatment in People With Malignant Pleural Mesothelioma NCT06037941 | Memorial Sloan Kettering Cancer Center | N/A |
| Withdrawn | Regorafenib With Tislelizumab in Patients With Selected Mismatch Repair-Proficient/Microsatellite Stable Cance NCT05582031 | Translational Research in Oncology | Phase 2 |
| Completed | Switch-Maintenance Gemcitabine After First-Line Chemotherapy In Patients With Malignant Pleural Mesothelioma NCT05660616 | Ain Shams University | Phase 2 |
| Completed | A Safety and Efficacy Study Evaluating CTX131 in Adult Subjects With Relapsed or Refractory Solid Tumors NCT05795595 | CRISPR Therapeutics AG | Phase 1 / Phase 2 |
| Recruiting | Integration of the PD-L1 Inhibitor Atezolizumab and WT1/DC Vaccination Into Platinum/Pemetrexed-based First-li NCT05765084 | University Hospital, Antwerp | Phase 1 / Phase 2 |
| Unknown | AMT-151 in Patients With Selected Advanced Solid Tumours NCT05498597 | Multitude Therapeutics Inc. | Phase 1 |
| Recruiting | The IMmunotherapy Pleural 5-ALA PDT NCT04400539 | University Hospital, Lille | Phase 2 |
| Completed | Observational Study in Patients With Previously Unresectable Malignant Pleural Mesothelioma Treated With Nivol NCT05308966 | Groupe Francais De Pneumo-Cancerologie | — |
| Unknown | Study of RSO-021 in Patients With Malignant Pleural Effusion Due to Advanced/Metastatic Solid Tumors Including NCT05278975 | RS Oncology LLC | Phase 1 / Phase 2 |
| Unknown | Effect of HITHOC After Pleurectomy Decortication for Treatment of Malignant Pleural Mesothelioma NCT05508555 | Ain Shams University | N/A |
| Active Not Recruiting | A Study of Pembrolizumab and Radiation Therapy in People With Mesothelioma NCT04897022 | Memorial Sloan Kettering Cancer Center | Phase 1 |
| Unknown | Real World Study of MPM in China NCT05042557 | Chinese Academy of Medical Sciences | — |
| Completed | SAKK 17/18 (ORIGIN) MPM & NSCLC >1st Line Gemci & Atezo Ph II NCT04480372 | Swiss Cancer Institute | Phase 2 |
| Completed | DuRvalumab With chEmotherapy as First Line treAtment in Advanced Pleural Mesothelioma NCT04334759 | PrECOG, LLC. | Phase 3 |
| Unknown | Neoadjuvant Toripalimab Combined With Chemotherapy in the Treatment of Malignant Pleural Mesothelioma NCT04713761 | Shanghai Pulmonary Hospital, Shanghai, China | Phase 2 |
| Completed | Evaluation of the Clinical/Biological Characteristics, Efficacy and Safety of Patients With Malignant Pleural NCT04775446 | Centre Hospitalier Intercommunal Creteil | — |
| Withdrawn | Pembrolizumab + Defactinib In Pleural Mesothelioma NCT04201145 | Raphael Bueno, MD | Phase 1 |
| Completed | Poly-ICLC (Hiltonol®) Vaccine In Malignant Pleural Mesothelioma NCT04525859 | Oncovir, Inc. | Phase 1 |
| Active Not Recruiting | A Study of Nivolumab and Chemotherapy Followed by Surgery for Mesothelioma NCT04162015 | Memorial Sloan Kettering Cancer Center | Phase 1 |
| Unknown | MTG201 Plus Nivolumab in Patients With Relapsed Pleural Mesothelioma NCT04013334 | Momotaro-Gene Inc. | Phase 2 |
| Unknown | Effect of Expression of CD74 and VEGF on Outcome of Treatment in Patients With Malignant Pleural Mesothelioma NCT02761863 | Ain Shams University | — |
| Recruiting | APG-2449 in Patients With Advanced Solid Tumors NCT03917043 | Ascentage Pharma Group Inc. | Phase 1 |
| Active Not Recruiting | Efficacy & Safety of rAd-IFN Administered With Celecoxib & Gemcitabine in Patients With Malignant Pleural Meso NCT03710876 | Ferring Ventures Limited | Phase 3 |
| Terminated | Nintedanib as Switch Maintenance Treatment of Pleural Malignant Mesothelioma NCT02863055 | European Organisation for Research and Treatment of Cancer - EORTC | Phase 2 |
| Completed | Autologous Dendritic Cell Vaccination in Mesothelioma NCT02649829 | University Hospital, Antwerp | Phase 1 / Phase 2 |
| Active Not Recruiting | Accelerated Hypofractionated Radiotherapy in the Treatment of Malignant Pleural Mesothelioma NCT03269227 | Istituto Romagnolo per lo Studio dei Tumori Dino Amadori IRST S.r.l. IRCCS | N/A |
| Completed | MesoTRAP: A Study Comparing Video-assisted Thoracoscopic Partial Pleurectomy/Decortication With Indwelling Ple NCT03412357 | Papworth Hospital NHS Foundation Trust | N/A |
| Completed | Clinical Study of YS110 in Patients With Malignant Pleural Mesothelioma NCT03177668 | Kissei Pharmaceutical Co., Ltd. | Phase 1 / Phase 2 |
| Terminated | Evaluation of CRS-207 With Pembrolizumab in Previously Treated Malignant Pleural Mesothelioma (MPM) NCT03175172 | Aduro Biotech, Inc. | Phase 2 |
| Unknown | Pleurectomy/ Decortication (P/D) Preceded or Followed by Chemotherapy in Patients With Early Stage MPM NCT02436733 | European Organisation for Research and Treatment of Cancer - EORTC | Phase 2 |
| Completed | Ipilimumab and Nivolumab in the Treatment of Malignant Pleural Mesothelioma NCT03048474 | The Netherlands Cancer Institute | Phase 2 |
| Unknown | uPAR-PET for Prognostication in Patients With Non-small Cell Lung Cancer, Malignant Pleural Mesothelioma and L NCT02755675 | Rigshospitalet, Denmark | Phase 2 |
| Completed | Alvopem® (Pemetrexed) Safety Assessment NCT04843007 | NanoAlvand | — |
| Completed | Transarterial Chemoperfusion: Cisplatin, Methotrexate, Gemcitabine for Unresectable Pleural Mesothelioma NCT02611037 | H. Lee Moffitt Cancer Center and Research Institute | Phase 2 |
| Completed | Intrapleural Photodynamic Therapy in a Multimodal Treatment for Patients With Malignant Pleural Mesothelioma NCT02662504 | University Hospital, Lille | Phase 2 |
| Withdrawn | Concurrent Pemetrexed/Cisplatin With Pleural Intensity Modulated Radiation Therapy for Patients With Unresecta NCT02639767 | Memorial Sloan Kettering Cancer Center | Phase 1 |
| Completed | Nivolumab in Patients With Recurrent Malignant Mesothelioma NCT02497508 | The Netherlands Cancer Institute | Phase 2 |
| Unknown | Four Versus Six Cycles of Pemetrexed/Platinum for MPM NCT02497053 | Ain Shams University | Phase 2 |
| Completed | Re-directed T Cells for the Treatment (FAP)-Positive Malignant Pleural Mesothelioma NCT01722149 | University of Zurich | EARLY_Phase 1 |
| Completed | A Study of BBI608 in Combination With Pemetrexed and Cisplatin in Adult Patients With Malignant Pleural Mesoth NCT02347917 | Sumitomo Pharma Co., Ltd. | Phase 1 / Phase 2 |
| Completed | Safety and Efficacy of TTFields (150 kHz) Concomitant With Pemetrexed and Cisplatin or Carboplatin in Malignan NCT02397928 | NovoCure Ltd. | Phase 2 |
| Completed | Safety and Efficacy of Listeria in Combination With Chemotherapy as Front-line Treatment for Malignant Pleural NCT01675765 | Aduro Biotech, Inc. | Phase 1 |
| Completed | MesomiR 1: A Phase I Study of TargomiRs as 2nd or 3rd Line Treatment for Patients With Recurrent MPM and NSCLC NCT02369198 | Asbestos Diseases Research Foundation | Phase 1 |
| Completed | Effect of FAS and FAS Ligand Polymorphisms on Patients With Platinum-Based -Treated Malignant Pleural Mesothel NCT02269878 | Ain Shams University | — |
| Terminated | Window of Opportunity Study of VS-6063 (Defactinib) in Surgical Resectable Malignant Pleural Mesothelioma Part NCT02004028 | Verastem, Inc. | Phase 2 |
| Terminated | Placebo Controlled Study of VS-6063 in Subjects With Malignant Pleural Mesothelioma NCT01870609 | Verastem, Inc. | Phase 2 |
| Completed | ATREUS - Phase II Study on the Activity of Trabectedin in Patients With Malignant Pleural Mesothelioma (MPM) NCT02194231 | Mario Negri Institute for Pharmacological Research | Phase 2 |
| Completed | Study of the Combination of Tivantinib Plus Pemetrexed and Carboplatin NCT02049060 | Armando Santoro, MD | Phase 1 / Phase 2 |
| Completed | Intracavitary Cisplatin-Fibrin Localized Chemotherapy After P/D or EPP for Malignant Pleural Mesothelioma NCT01644994 | University of Zurich | Phase 1 / Phase 2 |
| Completed | Pharmacogenetics Of Vinorelbine In Malignant Pleural Mesothelioma Patients NCT01865045 | Armando Santoro, MD | — |
| Completed | Intrapleural Administration of HSV1716 to Treat Patients With Malignant Pleural Mesothelioma. NCT01721018 | Virttu Biologics Limited | Phase 1 / Phase 2 |
| Completed | A Phase II Study of PF-03446962 in Patients With Advanced Malignant Pleural Mesothelioma NCT01486368 | NCIC Clinical Trials Group | Phase 2 |
| Completed | Autologous Redirected RNA Meso-CIR T Cells NCT01355965 | University of Pennsylvania | Phase 1 |
| Unknown | A Clinical Trial of ADI-PEG 20TM in Patients With Malignant Pleural Mesothelioma NCT01279967 | Barts & The London NHS Trust | Phase 2 |
| Completed | Galinpepimut-S (WT-1 Analog Peptide) Vaccine in Malignant Pleural Mesothelioma After Combined Modality Therapy NCT01265433 | Sellas Life Sciences Group | Phase 2 |
| Terminated | Pilot Study of Allogeneic Tumor Cell Vaccine With Metronomic Oral Cyclophosphamide and Celecoxib in Patients U NCT01143545 | National Cancer Institute (NCI) | Phase 1 |
| Completed | NGR015: Study in Second Line for Patient With Advanced Malignant Pleural Mesothelioma Pretreated With Pemetrex NCT01098266 | AGC Biologics S.p.A. | Phase 3 |
| Completed | Everolimus (RAD001) for the Treatment of Malignant Pleural Mesothelioma With Merlin/NF2 Loss as a Biomarker to NCT01024946 | Memorial Sloan Kettering Cancer Center | Phase 2 |
| Completed | Dendritic Cell-based Immunotherapy Combined With Low-dose Cyclophosphamide in Patients With Malignant Mesothel NCT01241682 | Erasmus Medical Center | Phase 1 |
| Unknown | Response Evaluation in Malignant Pleural Mesothelioma NCT00969098 | Istituto Clinico Humanitas | — |
| Completed | Standard Chemotherapy With of Without Axitinib in Malignant Mesothelioma NCT01211275 | The Netherlands Cancer Institute | Phase 1 / Phase 2 |
| Completed | Intrapleural Gene Transfer for Pleural Mesothelioma NCT01212367 | Abramson Cancer Center at Penn Medicine | Phase 1 |
| Completed | Molecular Predictors of Pemetrexed and Carboplatin Response in Malignant Pleural Mesothelioma (MPM) Patients NCT00867711 | Istituto Clinico Humanitas | — |
| Completed | An Efficacy Study of MORAb-009 (Amatuximab) in Subjects With Pleural Mesothelioma NCT00738582 | Morphotek | Phase 2 |
| Completed | Short Neoadjuvant Hemithoracic IMRT for MPM NCT00797719 | University Health Network, Toronto | Phase 1 / Phase 2 |
| Completed | Study of CBP501 + Pemetrexed + Cisplatin on MPM (Phase I/II) NCT00700336 | CanBas Co. Ltd. | Phase 1 / Phase 2 |
| Completed | Dasatinib in Resectable Malignant Pleural Mesothelioma NCT00652574 | M.D. Anderson Cancer Center | Phase 1 |
| Completed | Extrapleural Pneumonectomy /Pleurectomy Decortication, IHOC Cisplatin and Gemcitabine With Amifostine and Sodi NCT00571298 | Brigham and Women's Hospital | Phase 1 |
| Completed | Study of NGR-hTNF as Single Agent in Patients Affected by Advanced or Metastatic Malignant Pleural Mesotheliom NCT00484276 | AGC Biologics S.p.A. | Phase 2 |
| Completed | Safety Confirmation Study of Pemetrexed Plus Cisplatin in Patients With Malignant Pleural Mesothelioma NCT00386815 | Eli Lilly and Company | Phase 2 |
| Unknown | Palliative Treatment With Liposomal Doxorubicin Plus Cisplatin for Patients With Malignant Pleural Mesotheliom NCT00886028 | National Institute of Cancerología | Phase 2 |
| Completed | Dendritic Cell-based Immunotherapy in Mesothelioma NCT00280982 | Erasmus Medical Center | Phase 1 |
| Completed | Study of Carboplatin and Vinorelbine in Malignant Pleural Mesothelioma NCT00272558 | Rigshospitalet, Denmark | Phase 2 |
| Terminated | Pleurectomy/Decortication With Intraoperative Intrathoracic/Intraperitoneal Heated Cisplatin With Sodium Thios NCT00165503 | Dana-Farber Cancer Institute | Phase 2 |
| Completed | Extrapleural Pneumonectomy With Intraoperative Intrathoracic/Intraperitoneal Heated Cisplatin With Amifostine NCT00165516 | Dana-Farber Cancer Institute | Phase 2 |
| Completed | Gemcitabine in Long Infusion and Cisplatin for Malignant Pleural Mesothelioma Treatment NCT01243632 | Institute of Oncology Ljubljana | Phase 2 |
| Unknown | Trimodality Therapy for Malignant Pleural Mesothelioma NCT01343264 | HSK Wiesbaden | — |
| Completed | Pleurectomy/Decortication Followed by Intrathoracic/Intraperitoneal Heated Cisplatin for Malignant Pleural Mes NCT00165555 | Dana-Farber Cancer Institute | Phase 1 |
| Withdrawn | A Phase I/II Study of First Line Vorinostat With Pemetrexed-cisplatin, in Patients With Malignant Pleural Meso NCT01353482 | University College, London | Phase 1 / Phase 2 |